Pretreatment Serum Ip-10 Is Associated With The First Phase Decline Of Hcv-Rna And Outcome Of Therapy In Chronic Hepatitis C

arms than on PEG-IFNa2a.On CXR, one new case of radiologic interstitial findings was observed.No case of clinically relevant ILD was reported.In a multivariate analysis, a persistent decrease in post-treatment DlCO was associated with baseline DlCO, DLCO decline at week 12, gender and Asian region; but not to smoking status, alcohol use, HCV genotype, SVR, viral load at baseline, or baseline spirometry.Conclusion: Significant declines in DLCO during IFN-based treatment of hepatitis C are frequent, often persistent and of unclear clinical significance.These changes appear unrelated to viral variables.The potential mechanisms and implications for the risk of developing ILD on treatment warrant further research.